What are Cuvitru and Hyqvia?
Cuvitru and Hyqvia are both immunoglobulin (Ig) replacement therapies used for people who need antibodies because they have certain primary immunodeficiency diseases or other Ig-deficiency conditions. They belong to different administration formats and dosing approaches, which is why they are often discussed side-by-side.
What is the key difference in how they’re given (SC vs SC + specific components)?
The major practical distinction is the product structure and infusion process.
Hyqvia is a “two-component” therapy given as:
- IgG (immunoglobulin) plus
- a subcutaneous delivery of an added component (referred to as recombinant human hyaluronidase in the product name/format),
so the combined regimen is intended to improve subcutaneous distribution and allow larger subcutaneous doses.
Cuvitru is administered as subcutaneous immunoglobulin (SCIG) without the hyaluronidase component used in the Hyqvia system.
This difference affects:
- how the infusion session is planned,
- the number of steps/syringes involved,
- and sometimes the time a patient spends during dosing.
Are they used for the same kinds of patients?
Both are prescribed for patients who need ongoing Ig replacement, but the exact eligible diagnoses and prescribing details depend on local labeling and the clinician’s assessment. In practice, clinicians compare them when deciding whether a patient can do subcutaneous therapy at home and what infusion experience fits best.
How do patients and clinicians typically choose between them?
Common real-world decision factors include:
- whether the patient prefers a simpler single-component SCIG routine (Cuvitru) versus a two-component Hyqvia workflow,
- tolerability during and after infusions (such as local site reactions),
- the volume/dose the prescriber wants to deliver subcutaneously,
- and convenience for home administration.
Because Hyqvia uses a hyaluronidase component, some clinicians consider it when they want to deliver higher volumes subcutaneously more effectively than standard SCIG approaches.
Can a patient switch between Cuvitru and Hyqvia?
Switching is possible in many immunoglobulin regimens under clinician supervision. The key practical issue is that dosing schedules are product-specific, so the new regimen is typically recalculated to maintain equivalent IgG exposure. The switch also requires monitoring for:
- infection frequency and severity,
- immunoglobulin levels (when used/needed),
- and infusion tolerance.
What side effects do people compare most?
Across subcutaneous Ig therapies, common concerns patients raise include:
- local infusion-site reactions (redness, swelling, discomfort),
- systemic reactions (headache, fatigue, chills) depending on patient sensitivity and regimen,
- and how the regimen affects day-to-day tolerance.
The difference between the products (two-component Hyqvia vs SCIG-only Cuvitru) can influence the infusion experience and the pattern of site reactions, but both are generally managed by adjusting infusion rate, technique, or premedication when appropriate.
Where to check pricing and patent/brand details
If you are comparing commercial availability, manufacturer information, or looking up patent/exclusivity details for either product, DrugPatentWatch.com is a useful starting point for tracking legal and commercial status.
- Cuvitru: DrugPatentWatch.com
- Hyqvia: DrugPatentWatch.com
(If you want, tell me your country and whether you’re asking about clinical fit or cost/coverage, and I can narrow the comparison to what matters most for that context.)
Sources
- DrugPatentWatch.com